# US 2021/0277417 A1 · Methods of treating clrn1-associated hearing loss and/or vision loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277417 A1
- Document ID: US20210277417A1
- Status: Published application
- Kind: A1
- Application number: 17/253,658
- Filed: 2019-06-25
- Published: 2021-09-09
- Earliest claimed: 2018-06-25
- Assignees: Akouos, Inc.
- Applicants: Akouos, Inc.
- Inventors: Emmanuel John Simons; Robert Ng
- Web page: https://patentgrep.com/patent/US20210277417A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- C12N 15/86: Viral vectors
- A61K 9/0046: {Ear}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- A61P 27/16: Otologicals
- C07K 14/47: from mammals
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 15/67: General methods for enhancing the expression
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are compositions that include a single nucleic acid vector or two different nucleic acid vectors, and the use of these compositions to treat hearing loss and/or vision loss in a subject.

## Claims

### Claim at position 1

-228. (canceled)

### Claim 229

A method comprising:
introducing into a cochlea of a mammal a therapeutically effective amount of a composition comprising a single nucleic acid vector, wherein the vector comprises a first coding sequence encoding a first isoform of CLRN1 protein,
wherein the first coding sequence comprises a nucleotide sequence spanning two consecutive exons of a CLRN1 genomic DNA, and lacking an intronic sequence between the two consecutive introns.

### Claim 230 (depends on 229)

The method of claim 229, wherein the mammal is a human.

### Claim 231 (depends on 230)

The method of claim 230, wherein the mammal has been previously identified as having a defective endogenous CLRN1 gene.

### Claim 232

A composition comprising a single nucleic acid vector, wherein the vector comprises:
a first coding sequence encoding a first isoform of CLRN1 protein,
wherein the first coding sequence comprises a nucleotide sequence spanning two consecutive exons of a CLRN1 genomic DNA, and lacking an intronic sequence between the two consecutive introns.

### Claim 233 (depends on 232)

The composition of claim 232, wherein the first isoform of the CLRN1 protein comprises a sequence that is at least 95% identical to SEQ ID NO: 3.

### Claim 234 (depends on 232)

The composition of claim 232, wherein the first isoform of the CLRN1 protein comprises SEQ ID NO: 3.

### Claim 235 (depends on 232)

The composition of claim 232, wherein the single nucleic acid vector further comprises a 5′ untranslated region (UTR), a 3′ UTR, or both.

### Claim 236 (depends on 235)

The composition of claim 235, wherein the 5′ UTR comprises at least 10 contiguous nucleotides from SEQ ID NO: 12.

### Claim 237 (depends on 236)

The composition of claim 236, wherein the 5′ UTR comprises at least 20 contiguous nucleotides from SEQ ID NO: 12.

### Claim 238 (depends on 235)

The composition of claim 235, wherein the 3′ UTR comprises at least 10 contiguous nucleotides from SEQ ID NO: 36.

### Claim 239 (depends on 238)

The composition of claim 238, wherein the 3′ UTR comprises at least 20 contiguous nucleotides from SEQ ID NO: 36.

### Claim 240 (depends on 232)

The composition of claim 232, wherein the single nucleic acid vector is a plasmid, a transposon, a cosmid, an artificial chromosome, or a viral vector.

### Claim 241 (depends on 232)

The composition of claim 232, wherein the single nucleic acid vector is a human artificial chromosome (HAC), yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC), or a P1-derived artificial chromosome (PAC).

### Claim 242 (depends on 232)

The composition of claim 232, wherein the single nucleic acid vector is a viral vector selected from an adeno-associated virus (AAV) vector, an adenovirus vector, a lentivirus vector, or a retrovirus vector.

### Claim 243 (depends on 242)

The composition of claim 242, wherein the single nucleic acid vector is an AAV vector.

### Claim 244 (depends on 232)

The composition of claim 232, wherein the single nucleic acid vector further comprises one or both of a promoter and a Kozak sequence.

### Claim 245 (depends on 244)

The composition of claim 244, wherein the single nucleic acid vector comprises a promoter that is an inducible promoter, a constitutive promoter, or a tissue-specific promoter.

### Claim 246 (depends on 244)

The composition of claim 244, wherein the single nucleic acid vector further comprises a polyadenylation signal sequence.

### Claim 247 (depends on 232)

The composition of claim 232, further comprising a pharmaceutically acceptable excipient.

### Claim 248 (depends on 232)

A kit comprising a composition of claim 232.

### Claim 249 (depends on 232)

A method of increasing expression of a full-length CLRN1 protein in a mammalian cell, the method comprising introducing the composition of claim 232 into the mammalian cell.

### Claim 250 (depends on 232)

A method of increasing expression of a full-length CLRN1 protein in an inner hair cell, an outer hair cell, or both, in a cochlea of a mammal, the method comprising:
introducing into the cochlea of the mammal a therapeutically effective amount of the composition of claim 232.

### Claim 251 (depends on 232)

A method of increasing expression of a full-length CLRN1 protein in an eye of a mammal, the method comprising:
intraocularly administering to the eye of the mammal a therapeutically effective amount of the composition of claim 232.

### Claim 252 (depends on 232)

A method of treating hearing loss in a subject identified as having a defective CLRN1 gene, the method comprising:
administering a therapeutically effective amount of a composition of claim 232 into the cochlea of the subject.

### Claim 253 (depends on 232)

A method of treating vision loss in a subject identified as having a defective CLRN1 gene, the method comprising:
administering a therapeutically effective amount of a composition of claim 232 into the eye of the subject.
